{
    "ticker": "MGNX",
    "name": "MacroGenics, Inc.",
    "description": "MacroGenics, Inc. is a biotechnology company focused on developing innovative antibody-based therapeutics for the treatment of cancer and autoimmune diseases. Established in 2000 and headquartered in Rockville, Maryland, MacroGenics leverages its proprietary technology platforms to create differentiated monoclonal antibodies and antibody-drug conjugates. The company's lead product candidates include Margetuximab, an antibody designed to treat HER2-positive breast cancer, and several others currently in various stages of clinical development. MacroGenics is dedicated to advancing its pipeline through rigorous clinical trials and collaborations with strategic partners to enhance the effectiveness of its therapies. The company aims to bring transformative medicines to patients with unmet medical needs and is committed to scientific innovation and excellence in drug development. As of now, MacroGenics is actively working on expanding its portfolio and enhancing its capabilities in precision medicine, with a focus on ensuring that its therapies provide meaningful benefits to patients.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Rockville, Maryland, USA",
    "founded": "2000",
    "website": "https://www.macrogenics.com",
    "ceo": "Scott Koenig",
    "social_media": {
        "twitter": "https://twitter.com/MacroGenics",
        "linkedin": "https://www.linkedin.com/company/macrogenics"
    },
    "investor_relations": "https://www.macrogenics.com/investors",
    "key_executives": [
        {
            "name": "Scott Koenig",
            "position": "CEO"
        },
        {
            "name": "Julian Adams",
            "position": "President and Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Antibody-based Therapies",
            "products": [
                "Margetuximab",
                "Enoblituzumab",
                "MGD013"
            ]
        }
    ],
    "seo": {
        "meta_title": "MacroGenics, Inc. | Innovative Antibody-based Therapeutics",
        "meta_description": "Learn about MacroGenics, Inc., a biotechnology leader in developing antibody-based therapies for cancer and autoimmune diseases. Explore our innovative drug pipeline.",
        "keywords": [
            "MacroGenics",
            "Biotechnology",
            "Cancer Therapies",
            "Antibody-drug Conjugates",
            "Margetuximab"
        ]
    },
    "faq": [
        {
            "question": "What is MacroGenics known for?",
            "answer": "MacroGenics is known for developing innovative antibody-based therapeutics for cancer and autoimmune diseases."
        },
        {
            "question": "Who is the CEO of MacroGenics?",
            "answer": "Scott Koenig is the CEO of MacroGenics, Inc."
        },
        {
            "question": "Where is MacroGenics headquartered?",
            "answer": "MacroGenics is headquartered in Rockville, Maryland, USA."
        },
        {
            "question": "What are MacroGenics' main products?",
            "answer": "MacroGenics' main products include Margetuximab, Enoblituzumab, and MGD013."
        },
        {
            "question": "When was MacroGenics founded?",
            "answer": "MacroGenics was founded in 2000."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "BMY",
        "NVS"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "ILMN",
        "MRNA"
    ]
}